Ok - there's a bit to take in. I agree with holding off on DX3 until we have a successful DX1 ph1 trial, we simply can't afford to do both at once.
Our new chair used to be chief medical officer at CSL - not a bad company.
We have $5.3m in cash, I'm not sure how much we'll spend on the production run and ph 1 trial but we should have enough.
Everything hangs on a successful PR by our CDMO. If that works then we go straight into the ph1 trials and it's game on.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $4.731M | |||
| Open | High | Low | Value | Volume |
| 0.2¢ | 0.2¢ | 0.2¢ | $1.267K | 652.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 20 | 107100000 | 0.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.2¢ | 72591243 | 16 |
View Market Depth
| Last trade - 12.58pm 01/08/2025 (20 minute delay) ? |
| PAB (ASX) Chart |